Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (581-590 of 764) with videos related to

Pageof 77
Sort By:
International Journal of Cardiology|May 17, 2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionDeepak L Bhatt, Juan Carlos Kaski, Sean Delaney, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
Journal of Cardiovascular Development and Disease|June 25, 2025
Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI TrialLuis Ortega-Paz, Claudio Laudani, Alessandro Sionis, et al.
Journal of Clinical Medicine|June 12, 2026
Effect of Dapagliflozin on Myocardial Fibrosis After STEMI: A Double-Blind, Placebo-Controlled Randomized TrialLuis Ortega-Paz, Claudio Laudani, Carlos Igor Morr, et al.
American Heart Journal|October 8, 2020
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stentMarco Valgimigli, Davide Cao, Rajendra R Makkar, et al.
Thrombosis Research|September 27, 2005
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery diseaseDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
The American Journal of Cardiology|October 11, 2005
Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia geneDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
Circulation|January 12, 2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionFrancesco Franchi, Fabiana Rollini, Andrea Rivas, et al.
JACC. Basic to Translational Science|June 2, 2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic TestingFrancesco Franchi, Fabiana Rollini, Jose Rivas, et al.
JACC. Cardiovascular Interventions|March 26, 2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 StudyFrancesco Franchi, Gabriel Todd Faz, Fabiana Rollini, et al.
Pageof 77

Showing results (581-590 of 764) with videos related to

Sort By:
Pageof 77
International Journal of Cardiology|May 17, 2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionDeepak L Bhatt, Juan Carlos Kaski, Sean Delaney, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
Journal of Cardiovascular Development and Disease|June 25, 2025
Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI TrialLuis Ortega-Paz, Claudio Laudani, Alessandro Sionis, et al.
Journal of Clinical Medicine|June 12, 2026
Effect of Dapagliflozin on Myocardial Fibrosis After STEMI: A Double-Blind, Placebo-Controlled Randomized TrialLuis Ortega-Paz, Claudio Laudani, Carlos Igor Morr, et al.
American Heart Journal|October 8, 2020
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stentMarco Valgimigli, Davide Cao, Rajendra R Makkar, et al.
Thrombosis Research|September 27, 2005
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery diseaseDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
The American Journal of Cardiology|October 11, 2005
Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia geneDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
Circulation|January 12, 2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionFrancesco Franchi, Fabiana Rollini, Andrea Rivas, et al.
JACC. Basic to Translational Science|June 2, 2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic TestingFrancesco Franchi, Fabiana Rollini, Jose Rivas, et al.
JACC. Cardiovascular Interventions|March 26, 2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 StudyFrancesco Franchi, Gabriel Todd Faz, Fabiana Rollini, et al.
Pageof 77